---
title: "Evaxion A/S Wins Shareholder Approval for Expanded Equity and Convertible Financing Powers"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283662971.md"
description: "Evaxion A/S received shareholder approval for expanded financing powers at its Annual General Meeting on April 16, 2026. Shareholders approved the 2025 audited annual report, re-elected four directors, and appointed a new board member. Amendments to the Articles of Association allow the company to issue up to DKK 11.9 million in warrants and raise DKK 73.5 million via convertible loan notes, enhancing financial flexibility but risking share dilution. Analysts rate EVAX stock as a Buy with a $9.00 price target, though concerns about cash generation and profitability persist."
datetime: "2026-04-22T11:28:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283662971.md)
  - [en](https://longbridge.com/en/news/283662971.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283662971.md)
---

# Evaxion A/S Wins Shareholder Approval for Expanded Equity and Convertible Financing Powers

### Claim 30% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Evaxion Biotech ( (EVAX) ) just unveiled an update.

On April 16, 2026, Evaxion A/S held its Annual General Meeting, where shareholders representing 25.15% of outstanding ordinary shares approved the 2025 audited annual report and resolved that the year’s loss be carried forward. The meeting re-elected four directors, appointed Jens Bitsch-Nørhave as a new board member, and confirmed EY Godkendt Revisionspartnerselskab as auditor, reinforcing continuity in governance and oversight.

Shareholders also approved amendments to Evaxion’s Articles of Association to expand the board’s authority to issue up to DKK 11.9 million in warrants and to establish a new authorization to raise up to DKK 73.5 million via convertible loan notes, both without pre-emptive rights for existing shareholders. These changes, effective April 16, 2026, provide the company with greater flexibility to incentivize key personnel and access equity-linked financing, potentially supporting future growth but also opening the door to share dilution for current investors.

The most recent analyst rating on (EVAX) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.

**Spark’s Take on EVAX Stock**

According to Spark, TipRanks’ AI Analyst, EVAX is a Neutral.

The score is driven primarily by improved capitalization but still-weak cash generation and profitability. Technicals are moderately favorable with improving momentum, while valuation remains limited by losses. Earnings-call commentary adds support via clear milestone roadmap, strong EVX-01 results, and runway into H2 2027, tempered by dilution/partnering execution risks.

To see Spark’s full report on EVAX stock, click here.

**More about Evaxion Biotech**

Evaxion A/S, which also operates under the names Evaxion Biotech A/S and NovVac A/S, is a Danish biotechnology company that develops advanced software to enable novel immunotherapies and vaccines. The company focuses on leveraging computational platforms to design immune-based treatments, positioning it within the AI-driven biopharmaceutical and vaccine development space.

**Average Trading Volume:** 42,063

**Technical Sentiment Signal:** Sell

**Current Market Cap:** $37.45M

Learn more about EVAX stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [EVAX.US](https://longbridge.com/en/quote/EVAX.US.md)

## Related News & Research

- [Evaxion’s AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial | EVAX Stock News](https://longbridge.com/en/news/283185262.md)
- [Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress | EVAX Stock News](https://longbridge.com/en/news/286109610.md)
- [Atlassian’s New Flex AI Licensing Could Be A Game Changer For Atlassian (TEAM)](https://longbridge.com/en/news/286642450.md)
- [Appian partners with Snowflake to link AI process orchestration with Snowflake AI Data Cloud](https://longbridge.com/en/news/287020183.md)
- [Trillion-dollar Samsung faces a battle over who gets the AI profits](https://longbridge.com/en/news/287013238.md)